Mesoblast Limited MESO

Mesoblast announced FDA approval to implement a new potency assay, the T-cell Proliferation Inhibition BioAssay (TIBA), to release and monitor stability of all new commercial lots of its mesenchymal stromal cell product Ryoncil (remestemcel-L-rknd). TIBA will detect potency shifts that could arise from changes in manufacturing processes or production in new facilities and will be used alongside existing IL-2Rα inhibition and CAP potency assays as part of Ryoncil’s Biologics License release criteria. Ryoncil is the first FDA-approved industrial allogeneic MSC therapy and is approved for pediatric steroid-refractory acute graft-versus-host disease (SR-aGvHD) in patients aged 2 months and older. Mesoblast notes ongoing collaboration with FDA to advance manufacturing processes and quality control. The press release also highlights the company’s pipeline, intellectual property, and scale-up capabilities, with standard forward-looking statements and contact information. Enhances manufacturing quality control for Ryoncil across facilities, supporting scalability and regulatory compliance.

Mesoblast Limited reported substantial revenue growth reaching US$120 million. Revenue growth to US$120M indicates major financial improvement that can significantly boost company trajectory and investor sentiment.

Mesoblast Limited reported H2 earnings call highlights covering financial results, operational updates and strategic outlook. H2 earnings call delivers financial results and outlook that can moderately shape near-term investor sentiment and valuation.

Mesoblast Limited schedules a webcast to present financial results and corporate update. Financial results webcasts typically move stock prices in the near term.

Mesoblast Limited completed patient treatment in its chronic back pain study, resulting in a stock price increase. Trial completion represents pipeline progress for back pain treatment that can lift near-term investor sentiment and valuation.

Mesoblast Limited shares rose after completing patient treatment in its Phase 3 trial for chronic back pain. Phase 3 trial completion advances lead product toward data readout and potential approval, materially shifting company trajectory.

Mesoblast completed patient treatment in its pivotal Phase 3 trial for chronic low back pain. Completion of patient treatment in pivotal Phase 3 trial advances Mesoblast's lead candidate toward potential regulatory approval and commercialization.

Mesoblast Limited achieved net revenues of US$36M from Ryoncil in the quarter and US$115M for the first full year of product launch. Strong first-year revenues from Ryoncil signal successful product launch with major positive effects on future performance.

Mesoblast reaches target of 300 treated patients in pivotal Phase 3 trial for chronic low back pain. Reaching Phase 3 enrollment target advances potential product approval and revenue generation.

Mesoblast Limited reports Ryoncil® net revenue of US$36M for the quarter ended 30 June 2026. US$36M quarterly revenue from lead product Ryoncil® signals major financial gains and trajectory shift for Mesoblast.

Mesoblast receives BLA filing number and requests modular review for Rexlemestrocel-L in end-stage heart failure patients with LVADs. BLA filing and modular review request mark major regulatory progress for lead heart failure product, likely shifting company trajectory and investor outlook.

Mesoblast draws US$50 million from five-year non-dilutive facility. Non-dilutive $50 million funding improves Mesoblast liquidity and operational runway without share dilution.

Mesoblast Limited (MESO, ASX:MSB) completed enrollment in its RMAT-designated Phase 3 trial, marking a major milestone that reshapes its investment narrative by de-risking the path to FDA approval and potential commercialization. Completion of RMAT Phase 3 enrollment de-risks clinical development, accelerates potential regulatory approval, and significantly boosts investor sentiment and stock trajectory.

Mesoblast reports Ryoncil net revenues of US$30.3 million and improved net operating cash spend of US$4.1 million for the quarter. Ryoncil's $30.3M revenue demonstrates successful commercialization while reduced $4.1M cash burn improves financial sustainability.

Mesoblast Limited achieves patient recruitment target in its pivotal Phase 3 trial evaluating rexlemestrocel-L for chronic low back pain due to degenerative disc disease. Reaching full enrollment in a pivotal Phase 3 trial de-risks the program and positions Mesoblast closer to potential regulatory approval and commercialization.

Mesoblast Ltd (MESO) secures exclusive rights to a vital platform. Securing exclusive rights to a vital platform enables major advancements in product pipeline and competitive positioning.

Mesoblast Limited's share price has weakened recently amid conflicting growth signals, prompting a valuation reassessment. Share price weakness and conflicting growth signals could moderately impact investor sentiment and valuation perceptions.

Mesoblast Limited (MESO) named one of the best long-term ASX stocks to buy right now. Positive long-term buy recommendation moderately boosts investor sentiment and market perception.

Mesoblast Limited acquires Chimeric Antigen Receptor (CAR) platform technology to develop precision-enhanced cell products. Acquisition of CAR platform enables major expansion into precision cell therapies, significantly bolstering Mesoblast's pipeline and market positioning.

Gregory George bought 32% more shares in Mesoblast Limited (MESO), increasing his stake and signaling confidence in the company's prospects. Substantial insider purchase signals confidence, likely boosting market sentiment and stock performance moderately in the short term.

Mesoblast Limited (MESO) receives FDA IND clearance to directly proceed to registrational trial for Ryoncil® approval in Duchenne Muscular Dystrophy. FDA IND clearance enables direct advancement to registrational trial for Ryoncil in DMD, positioning Mesoblast for potential approval and profoundly transforming its competitive standing and long-term prospects.

Mesoblast (ASX:MSB) shares dropped 11.0% after FDA cleared registrational trial for Ryoncil in Duchenne muscular dystrophy, prompting questions on whether the bull case has changed. FDA clearance for registrational DMD trial of Ryoncil marks a major regulatory milestone advancing Mesoblast's pipeline toward potential approval.

Mesoblast's R&D Day highlighted Ryonsel gaining traction, Phase III trial for back pain nearing completion, and new initiatives on the horizon. Pipeline advancements including Ryonsel momentum, imminent Phase III readout, and new programs position Mesoblast for significant growth and investor interest.

Mesoblast Limited's R&D Day highlighted significant commercial progress and platform innovations. Significant commercial progress and platform innovations showcased at R&D Day represent major strategic advancements likely to enhance Mesoblast's competitive position and investor sentiment.

Mesoblast Limited (MESO) received FDA IND clearance to directly advance Ryoncil® to a registrational trial for Duchenne Muscular Dystrophy, paving the way for potential approval. FDA IND clearance propels Mesoblast directly to registrational trial for Ryoncil in DMD, a transformative step toward approval that redefines the company's competitive position and long-term prospects.

Mesoblast Limited's Ryoncil® generated net sales of US$30.3 million in the March quarter, continuing a successful first-year launch. Ryoncil's $30.3M first-quarter sales signal strong commercial uptake, significantly enhancing Mesoblast's revenue trajectory and investor confidence.

Mesoblast Limited appoints Dr. Teresa Montagut as Head of Clinical Development and Medical Affairs, bringing her extensive experience in oncology drug development from roles at Roche and other biotech firms. Appointing a seasoned clinical development leader enhances Mesoblast's pipeline advancement and regulatory strategy, significantly impacting future performance.

Mesoblast (ASX:MSB) shares dropped 7.1% after issuing first 2026 revenue guidance for Ryoncil, prompting questions on whether the bull case remains intact. First 2026 Ryoncil revenue guidance triggered a 7.1% stock drop, signaling major shift in investor sentiment and future performance expectations.

Mesoblast Limited shared H1 earnings call highlights, detailing financial performance, operational updates, and strategic outlook. H1 earnings call highlights cover financial results, pipeline progress, and guidance, significantly impacting investor sentiment and stock trajectory.

Mesoblast Limited's Ryoncil® generates profits that underpin a substantial growth pipeline. Ryoncil profits provide revenue to fund Mesoblast's growth pipeline, signaling major positive shift in financial and developmental trajectory.